Kamada Ltd. (NASDAQ:KMDA) Forecasted to Post Q4 2024 Earnings of $0.13 Per Share

Kamada Ltd. (NASDAQ:KMDA) – Investment analysts at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for Kamada in a research report issued to clients and investors on Thursday, May 9th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.13 per share for the quarter, up from their prior estimate of $0.06. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s FY2025 earnings at $0.39 EPS and FY2027 earnings at $0.67 EPS.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.04. Kamada had a net margin of 8.33% and a return on equity of 5.50%. The firm had revenue of $36.43 million for the quarter, compared to analysts’ expectations of $37.71 million.

Kamada Stock Performance

NASDAQ KMDA opened at $5.53 on Monday. The business has a fifty day moving average price of $5.54 and a 200 day moving average price of $5.54. The company has a market cap of $317.86 million, a P/E ratio of 24.07 and a beta of 1.05. Kamada has a one year low of $4.08 and a one year high of $6.53.

Institutional Trading of Kamada

A number of hedge funds have recently bought and sold shares of KMDA. EWA LLC acquired a new position in shares of Kamada during the 4th quarter worth approximately $68,000. Calton & Associates Inc. purchased a new stake in Kamada in the 4th quarter valued at $111,000. Y.D. More Investments Ltd increased its stake in shares of Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 15,000 shares during the last quarter. Aristides Capital LLC raised its holdings in shares of Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 16,635 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Kamada by 8.2% in the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares during the period. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.